Insider Selling: GRAIL (NASDAQ:GRAL) CFO Sells $671,579.00 in Stock

Key Points

• GRAIL CFO Aaron Freidin sold 7,900 shares at an average price of $85.01, totaling $671,579, under a pre-arranged Rule 10b5-1 trading plan. He continues to own 253,083 shares valued at approximately $21.5 million.
• GRAIL shares recently traded at $79.37, within a 12-month range of $30.82 to $118.84. The company’s latest quarter showed a smaller-than-expected loss of $2.56 per share and revenue of $44.69 million, above analyst estimates.
• Analyst sentiment is mixed, with four Buy, five Hold, and one Sell rating; the consensus rating is Hold with a target price of $67.78.

GRAIL, Inc. (NASDAQ:GRAL - Get Free Report) CFO Aaron Freidin sold 7,900 shares of GRAIL stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $85.01, for a total value of $671,579.00. Following the completion of the transaction, the chief financial officer owned 253,083 shares in the company, valued at $21,514,585.83. This represents a 3.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

GRAIL Price Performance

GRAL traded down $0.63 on Monday, hitting $79.37. The company had a trading volume of 555,941 shares, compared to its average volume of 781,912. The stock has a fifty day moving average price of $71.28 and a 200-day moving average price of $63.22. GRAIL, Inc. has a 12-month low of $30.82 and a 12-month high of $118.84.

GRAIL (NASDAQ:GRAL - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) EPS for the quarter, beating the consensus estimate of ($2.66) by $0.10. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. The business had revenue of $44.69 million during the quarter, compared to analyst estimates of $42.39 million. Research analysts anticipate that GRAIL, Inc. will post -10.41 earnings per share for the current fiscal year.

Institutional Trading of GRAIL

Several large investors have recently bought and sold shares of GRAL. HighTower Advisors LLC raised its holdings in shares of GRAIL by 3.5% in the second quarter. HighTower Advisors LLC now owns 40,565 shares of the company's stock worth $2,769,000 after buying an additional 1,357 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of GRAIL during the second quarter valued at $1,171,000. California State Teachers Retirement System grew its holdings in shares of GRAIL by 6,569.8% during the second quarter. California State Teachers Retirement System now owns 2,966,058 shares of the company's stock valued at $202,493,000 after buying an additional 2,921,588 shares during the last quarter. HB Wealth Management LLC acquired a new position in shares of GRAIL in the 2nd quarter valued at $217,000. Finally, William John Sempolinski purchased a new position in GRAIL in the 2nd quarter worth $488,000.

Analyst Ratings Changes

Several research firms have issued reports on GRAL. The Goldman Sachs Group started coverage on shares of GRAIL in a report on Friday, June 5th. They issued a "neutral" rating and a $60.00 price target on the stock. TD Cowen reissued a "buy" rating on shares of GRAIL in a research report on Wednesday, July 15th. Mizuho boosted their target price on GRAIL from $58.00 to $65.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 15th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of GRAIL in a research report on Friday, July 17th. Finally, Wall Street Zen upgraded GRAIL from a "sell" rating to a "hold" rating in a research note on Saturday, May 9th. Four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $67.78.

About GRAIL

GRAIL, Inc NASDAQ: GRAL is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company's platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source